hcv in 3

HCV-IN-3 is a hepatitis C virus (HCV) NS3 4a protein inhibitor (IC50: 20 μM; Kd: 29 μM).

HCV-IN-30 是 HCV NS5A 复制复合物的抑制剂（基因型 1a 和 1b 复制子的 IC50 = 901 和 102 nM）。

HCV-IN-38 是选择性的、有效的、口服具有活力的丙型肝炎病毒 (HCV) 抑制剂，其EC50值为15 nM，SI 值为431。HCV-IN-38 具有良好的安全性及口服药代动力学，表现出较高的抗HCV 活性和较低的细胞毒性作用。

HCV-IN-35 是 HCV 的有效抑制剂，表现出潜力进行感染性疾病的研究。

HCV-IN-36 是口服具有活力的HCV 进入抑制剂，表现出良好的抗病毒作用 (EC50: 0.016 μM, CC50: 8.78 μM)。

HCV-IN-33 (Compound (S)-3i) 是 HCV 进入抑制剂。

HCV-IN-34 是口服具有活力的 HCV 进入抑制剂。HCV-IN-35 表现出良好的抗病毒效果 (EC50: 0.010 μM, CC50: 7.50 μM)。

HCV-IN-37 是 HCV 的有效抑制剂。HCV-IN-37 以 15 mg kg 的单剂量对大鼠口服给药后，能够在大鼠血浆中持久存在。活性衍生物 HCV-IN-37 的高效力主要是由对病毒进入阶段的抑制作用驱动。

HCV-IN-31 是一种HCV 抑制剂，EC50 EC95值为15.7 μM。

2',3'-Isopropylideneuridine是一种核苷衍生物，已在多项研究中显示出抗病毒活性，特别是针对黄病毒科（Flaviviridae）成员，如丙型肝炎病毒（HCV）。

Daclatasvir (EBP 883) 是一种高度选择性的 HCV NS5A 抑制剂，EC50 为 9-50 pM，适用于细胞培养中的多种 HCV 复制子基因型和 JFH-1 基因型 2a 感染性病毒。

Beclabuvir (BMS-791325) 是一种高效的 NS5A 复制复合物抑制剂，抑制 HCV 基因型 1，2，4，5 表达的 NS5B 蛋白活性，可用于研究 HCV 感染。

DDX3-IN-1 is a DEAD-box polypeptide 3 (DDX3) inhibitor with CC50 of 50 and 36 μM for HIV and HCV, respectively. Antiviral activity.

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.

HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.

Ciluprevir is an effective and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrea

Paritaprevir free base (ABT-450) 是一种口服生物可利用的合成酰基磺酰胺抑制剂，可抑制丙型肝炎病毒 (HCV) 蛋白酶复合物，由非结构蛋白 3 和 4A (NS3 NS4A) 组成，对 HCV 基因型 1 具有潜在活性。 给药后，paritaprevir 可逆地结合 HCV NS3 NS4A 蛋白酶的活性中心和结合位点，并阻止 NS3 NS4A 蛋白酶介导的多蛋白成熟。这会破坏病毒蛋白的加工和病毒复制复合物的形成，从而抑制病毒在 HCV 基因型 1 感染的宿主细胞中的复制。 NS3 是一种丝氨酸蛋白酶，对于 HCV 多蛋白内多个位点的蛋白水解切割至关重要，并且在 HCV 核糖核酸 (RNA) 复制过程中起关键作用。 NS4A 是 NS3 的激活因子。 HCV 是属于黄病毒科的一种小的、有包膜的单链 RNA 病毒，感染与肝细胞癌 (HCC) 的发展有关。

6-Hydroxypyridin-3-ylboronic acid is a heterocyclic building block.1,2It has been used in the synthesis of non-nucleoside inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructural protein 5B (NS5B).16-Hydroxypyridin-3-ylboronic acid has also been used in the synthesis of mammalian target of rapamycin (mTOR) inhibitors.2 1.Hendricks, R.T., Spencer, S.R., Blake, J.F., et al.3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymeraseBioorg. Med. Chem. Lett.19(2)410-414(2009) 2.Verheijen, J.C., Richard, D.J., Curran, K., et al.Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and sselective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituentJ. Med. Chem.52(24)8010-8024(2009)

Ribavirin-13C5is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers. 1.Gilbert, B.E., and Knight, V.Biochemistry and clinical applications of ribavirinAntimicrob. Agents Chemother.30(2)201-205(1986) 2.Gordon, C.J., Tchesnokov, E.P., Woolner, E., et al.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.295(20)6785-6797(2020) 3.Kirsi, J.J., North, J.A., McKernan, P.A., et al.Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agentAntimicrob. Agents Chemother.24(3)353-361(1983) 4.Wang, M., Cao, R., Zhang, L., et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30(3)269-271(2020) 5.Wilson, S.Z., Knight, V., Wyde, P.R., et al.Amantadine and ribavirin aerosol treatment of influenza A and B infection in miceAntimicrob. Agents Chemother.17(4)642-648(1980)

Beclabuvir, also known as BMS-791325, is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50) below 28 nM. In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. B

NS5A-IN-3 (Compound 15) 为高效NS5A抑制剂，对HCV基因型1b显示出高效力，并对基因型3a (GT 3a) 活性提升以及展现出良好的代谢稳定性。NS5A-IN-3相较于daclatasvir，对基因型1b具有更高的耐药门槛。

PSI-353661 (GS-558093) 是一种嘌呤核苷酸类NS5B 聚合酶抑制剂，可抵抗HCV 感染。PSI-353661抑制野生型和 S282T 抵抗性复制子HCV 的EC90s 分别为 8 nM 和 11 nM。PSI-353661 可在人原代肝细胞中产生高浓度的活性三磷酸。

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].